Applying science to addressing climate change
Posted by
18-Oct-2017
We are working with the Science-Based Target Initiative to ensure that we meet our climate change goals, that is to say rendering our operations carbon neutral by 2030. This project is a joint initiative by the United Nations, the Climate Disclosure Project, the World Resources Institute and the World Wide Fund for Nature. It supports organisations – currently including 300 companies – in setting climate targets in line with the COP21 climate summit in Paris.
The commitment by 195 countries to limit the increase of global temperature by the end of the century to well below 2˚C must be translated into a robust set of specific targets for companies like ours.
Our promise: carbon neutrality by 2030
As our Green Strategy shows, we take our responsibility to the planet very seriously. Our goal is to develop and produce medicines in the most environmentally sustainable way possible. That means reducing our carbon footprint, our water consumption and our waste production across the company.
Through the Science-Based Target Initiative, we have confirmed our climate targets to make our operations carbon neutral by 2030 . We are now working to define targets for activities in our value chain which we do not control directly. This includes activities performed, for example, by suppliers and Contract Manufacturing Organisations on behalf of our company.
In addition to our robust strategy to reduce carbon emissions, our company has launched two reforestation projects and another designed to avoid deforestation.
These projects will compensate for the carbon emissions we cannot reduce in the short term.
The transition to a low-carbon economy is accelerating globally. Industry leaders must step up innovation and improve efficiencies if we are to reach our shared goals. By applying science to one of the biggest challenges in the world, we will play our part in preparing UCB for the future.
The commitment by 195 countries to limit the increase of global temperature by the end of the century to well below 2˚C must be translated into a robust set of specific targets for companies like ours.
Our promise: carbon neutrality by 2030
As our Green Strategy shows, we take our responsibility to the planet very seriously. Our goal is to develop and produce medicines in the most environmentally sustainable way possible. That means reducing our carbon footprint, our water consumption and our waste production across the company.
Through the Science-Based Target Initiative, we have confirmed our climate targets to make our operations carbon neutral by 2030 . We are now working to define targets for activities in our value chain which we do not control directly. This includes activities performed, for example, by suppliers and Contract Manufacturing Organisations on behalf of our company.
In addition to our robust strategy to reduce carbon emissions, our company has launched two reforestation projects and another designed to avoid deforestation.
These projects will compensate for the carbon emissions we cannot reduce in the short term.
The transition to a low-carbon economy is accelerating globally. Industry leaders must step up innovation and improve efficiencies if we are to reach our shared goals. By applying science to one of the biggest challenges in the world, we will play our part in preparing UCB for the future.
Leave a Comment